9f45ce65661fd03d00a878f538d1f033942a2f606da68758c07c9ec834251791

Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

5b5a0ffb74c6927b677c74f64d8583f615ec0c857c4d0dcc4ec41f3b9d232182

e098392f6b35abb59816e3885f3f761bb6d54614f060c8f9f9279840190dcd1f

Number of Patients Enrolled (#)

Number of Clinical Sites (#)

Number of Countries (#)

HAE Attacks Treated (>600) (#)

HAE Attacks Treated (>800) (#)

HAE Attacks Treated (>1,700) (#)

ddc4a69a2705af65f8255eeb8f98be5e3ef9029b8b00953463b3236b139472fe

23794d91c53ae875c8e247d72561e35d9d06ee07c70c9e0dbcc977a6d161504a

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical needs. The company is primarily focused on developing treatments for hereditary angioedema (HAE), a rare genetic condition characterized by episodes of painful swelling. KalVista does not currently sell any products but is advancing its lead candidate, sebetralstat, through regulatory approval processes and conducting preclinical research on additional therapeutic programs.  **[0000950170-23-032298_kalv-20230430.htm:5]** **[0000950170-24-082965_kalv-20240430.htm:5]** **[0000950170-24-082965_kalv-20240430.htm:90]** **[0000950170-23-032298_kalv-20230430.htm:113]** **[0000950170-24-082965_kalv-20240430.htm:121]** 

1. **Sebetralstat** - A novel, small molecule plasma kallikrein inhibitor being developed as the first oral, on-demand therapy for hereditary angioedema (HAE). The drug has completed the phase 3 KONFIDENT trial and is under regulatory review following the submission of a New Drug Application (NDA) in June 2024.  **[0000950170-24-082965_kalv-20240430.htm:5]** **[0000950170-24-082965_kalv-20240430.htm:90]** **[0000950170-24-082965_kalv-20240430.htm:121]** 

2. **Factor XIIa Inhibitor Program** - A preclinical program focused on developing oral Factor XIIa inhibitors for next-generation HAE therapeutics. This program also explores potential applications in other diseases with high unmet medical needs.  **[0000950170-23-032298_kalv-20230430.htm:5]** **[0000950170-24-082965_kalv-20240430.htm:5]** **[0000950170-24-082965_kalv-20240430.htm:90]**

0c438a7d9769653a66ce22e052ae43b319fcf69ce9117b0a753263c45629de9a

- License Revenue

- Grant Income

Total Revenue

165080c1af53c42ae243fb3f1c6447b0028ae7dec2bd59fbe496185910b82d4e

| Name                  | Position                  | Start Date        | Short Bio                                                                                                                                                                                                 |
|-----------------------|---------------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Benjamin L. Palleiko  | Chief Executive Officer   | March 7, 2024     | Benjamin L. Palleiko was appointed as CEO on **March 7, 2024**. He joined KalVista in **2016** as CFO and has been instrumental in its growth from a UK-based private research entity to a multinational pre-commercial organization.  **[0001193125-24-061344_d808049dex991.htm:0]**         |
| Paul K. Audhya        | Chief Medical Officer     | May 2021          | **Paul K. Audhya, M.D., M.B.A.** has served as CMO since **May 2021**. He previously held senior roles at Arena Pharmaceuticals, Vertex Pharmaceuticals, and others. He earned his B.A. and M.D. from NYU and an M.B.A. from Pepperdine University.  **[0001193125-24-205356_d791142ddef14a.htm:33]** **[0001193125-23-212312_d444568ddef14a.htm:33]** **[0001193125-23-203858_d444568dpre14a.htm:33]**  |
| Christopher M. Yea    | Chief Development Officer | November 2015     | **Christopher M. Yea, Ph.D.** has been CDO since **November 2015**. Prior to KalVista, he was COO at Vantia, Ltd. and led the Biology group at Ferring Pharmaceuticals. He holds a B.Sc. and a Ph.D. in Biochemistry from the University of Bristol, UK.  **[0001193125-24-205356_d791142ddef14a.htm:33]** **[0001193125-22-226471_d378074ddef14a.htm:27]** **[0001193125-23-212312_d444568ddef14a.htm:33]**  |
| Brian Piekos          | Chief Financial Officer   | September 9, 2024 | Brian Piekos was appointed as CFO effective **September 9, 2024**. He has over 25 years of experience in the biopharmaceutical industry, previously serving as CFO at Elicio Therapeutics and others.  **[0000950170-24-105182_kalv-20240906.htm:1]** **[0000950170-24-133693_kalv-ex99_1.htm:1]**                                       |
| Jeb Ledell            | Chief Operating Officer   | December 16, 2024 | Jeb Ledell was appointed as COO effective **December 16, 2024**. He has over 20 years of leadership experience in biotechnology, previously serving as COO at AVEO Pharmaceuticals and others.  **[0001193125-24-279016_d866245dex991.htm:0]** **[0001193125-24-279016_d866245d8k.htm:1]**                                             |
| Laurence Reid, Ph.D.  | Board Member              | November 23, 2024 | Laurence Reid, Ph.D., was appointed to the Board on **November 23, 2024**. He has over three decades of experience in biotech leadership, previously serving as CEO of Decibel Therapeutics and holding roles at Third Rock Ventures and others.  **[0001193125-24-265612_d851354dex991.htm:0]** **[0001193125-24-265612_d851354d8k.htm:1]**  |

151cfc0cdf7bf4f8977c5e3b460192d7043512cd901231d9cb9267152fcf0246

Kalvista Pharmaceuticals Inc (KALV)

Financials